|
Newborn Screening Coding and Terminology Guide
|
Resource Development
|
CDC, FDA, HRSA, IOS
|
NLM, NHGRI, NHLBI, NICHD
|
This ongoing collaboration develops, supplements, and publicizes a free online resource with guidance to help promote the efficient electronic exchange of standardized newborn screening data. Related efforts include studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children.
|
|
Newborn Screening Federal Partners Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NLM
|
The federal members of the Advisory Committee on Heritable Disorders in Newborns and Children meet monthly to share information about newborn screening activities.
|
|
Next Generation Microfluidics Workshop
|
Meeting/ Workshop
|
FDA
|
NHLBI
|
This workshop focused on discussion of the state of the microfluidics (MF) field in biomedical applications, limitations in the field of MF, and how to move the field forward to extract the maximum utility to help patients. This meeting was a call to educate colleagues at the National Institutes of Health (NIH) about what can be done collectively to enable better research and move closer to translational applications, and bring more products to researchers in the MF space and to clinicians and patients.
|
|
NGSP (formerly the National Glycohemoglobin Standardization Program) (NGSP)
|
Resource Development
|
CDC
|
NIDDK, CC
|
The purpose of the NGSP (formerly the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes.
|
|
NIA IMPACT Collaboratory Transforming Dementia Care (IMPACT Collaboratory)
|
Research Initiative
|
CDC
|
NIA
|
The mission of the IMbedded Pragmatic Alzheimers disease (AD) and AD Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is to build the nation’s capacity to conduct pragmatic clinical trials of interventions embedded within health care systems for people living with dementia and their care partners.
The IMPACT Collaboratory accomplishes this mission by: developing and disseminating best practice research methods; supporting the design and conduct of pragmatic trials, including pilot studies; building investigator capacity through training and knowledge generation; catalyzing collaboration among stakeholders, healthcare providers, and investigators; and ensuring the research includes culturally-tailored interventions and people from diverse and under-represented backgrounds.
|
|
NIAID NIBIB BARDA DOD Monday Meetings
|
Other
|
CDC, ASPR
|
NIAID, NIBIB
|
The group discusses topical COVID diagnostics and agency-specific issues.
|
|
NIAID-CDC Joint US Partnership Implementing TB Elimination Research (JUPITER)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
Through bi-weekly teleconferences, the Joint US Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the NIAID and the CDC. This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate.
|
|
NIAID/Armed Forces Radiobiology Research Institute (AFRRI) Research Coordination Team (RCT)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NIAID
|
The Research Coordinating Team (RCT) has been successfully reestablished and will continue to meet quarterly in 2021. The purpose of the RCT is to discuss progress, resolve any concerns and to explore new areas of research to be conducted under the IAA.
|
|
NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database.
|
|
NIAID/FDA/BARDA Meeting on Cutaneous Radiation Injuries
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID, NIGMS
|
A meeting was held May 6-7, 2019. The purpose of this meeting was to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the skin
|